been approved for MS spasticity in sixteen countries and is currently undergoing clinical trials in the United States.
Looking back, humans have shaped cannabis chemistry for generations. We selectively grew strains with the most helpful properties, including – perhaps particularly – to combat seizures. The chemical production was guided towards the optimal overall effect; not necessarily the most singly potent compounds. The combinatorial (aka entourage) effect of cannabinoids may well be the most effective clinical approach. With more research we will better understand – and deliver to patients - the chemical compositions that best keep the ghosts away.
@ADRPHD
References:
1. Cannabis and epilepsy: An ancient treatment returns to the fore. Russo EB. Epilepsy Behav. 2017 May;70(Pt B):292-297. doi: 10.1016/j.yebeh.2016.09.040. PMID: 27989385
2. Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview. C a p a s s o A . O p e n N e u r o l J . 2 0 1 7 D e c 1 8 ; 11 : 6 1 - 7 3 . d o i : 10.2174/1874205X01711010061. PMID: 29290836
3. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? Perucca E. J Epilepsy Res. 2017 Dec; 7(2): 61–76. doi: 10.14581/jer.17012. PMID: 29344464
4. Practical considerations in medical cannabis administration and dosing. MacCallum CA, Russo EB. Eur J Intern Med. 2018 Jan 4. pii: S0953-6205(18)30004-9. doi: 10.1016/j.ejim.2018.01.004. PMID: 29307505
5. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Sulak D, Saneto R, Goldstein B. Epilepsy Behav. 2017 May;70(Pt B):328-333. doi: 10.1016/j.yebeh.2016.12.032. PMID: 28254350
6. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE Study Group. Lancet. 2018 Jan 25. pii: S0140-6736(18)30136-3. doi: 10.1016/ S0140-6736(18)30136-3. PMID: 29395273
Adam D. Richardson, Chief Scientific Officer, Aegis Biotech
Dr. Adam is an analytical chemist with over 20 years of experience in the natural products and biomedical research fields. He brings his passion for natural product therapeutics and expertise in biomedical research to AEGIS to help develop cannabis-based products for cancer, epilepsy, and other diseases.
59